Orforglipron Side Effects: Complete Guide

Understanding Orforglipron and Its Potential Side Effects

Orforglipron was approved by the US FDA on April 1, 2026, as Foundayo, for chronic weight management in adults with obesity, or overweight with at least one weight-related condition. It has also been studied for type 2 diabetes, which is not an approved use as of its July 2026 US label, and approval outside the US varies. As an oral, once-daily GLP-1 (glucagon-like peptide-1) receptor agonist, it is taken differently from many other medications in its class, which are typically injectable. Like any medication, orforglipron has potential side effects, which are listed in its prescribing information. Understanding these can help you have a more informed conversation with your doctor.

This guide provides a balanced overview of the side effects associated with orforglipron, from the most common to the more serious but less frequent. The goal is to offer clear, trustworthy information without hype or alarm. Consult your healthcare provider before starting any medication.

How GLP-1 Medications Work

To understand the side effects, it helps to know how orforglipron works. GLP-1 receptor agonists mimic a natural hormone in your body that is released after you eat. This hormone has several effects: it helps the pancreas release insulin in response to blood sugar, it slows down how quickly food leaves your stomach, and it sends signals of fullness to your brain.

Because this class of medication directly affects the digestive system, it’s not surprising that the most common side effects are gastrointestinal in nature. These effects are often most noticeable when you first start the medication or when the dose is increased.

Common Side Effects of Orforglipron

Clinical trial data shows that the most frequently reported side effects are related to the digestive system. In the US label, side effects reported by at least 5% of people included nausea, constipation, diarrhoea, vomiting, indigestion, abdominal pain, headache, bloating, tiredness, burping, acid reflux, wind and hair loss. In the pooled weight-management trials, about a quarter to a third of people on orforglipron reported nausea (26% to 35% depending on dose), compared with 10% on placebo, and 8% stopped treatment because of side effects, compared with 3% on placebo. For many people, these effects are mild to moderate and often decrease over time as their bodies adjust to the medication.

Nausea and Vomiting

Nausea is the most common side effect associated with orforglipron and other GLP-1 medications. It can range from a mild, fleeting feeling to more significant discomfort, and may sometimes be accompanied by vomiting. This typically occurs as your body gets used to the drug's effect of slowing down digestion.

Diarrhea

Diarrhea is another frequently reported gastrointestinal issue. Like nausea, it is often most pronounced during the initial phase of treatment or after a dose increase. Staying hydrated is particularly important if you experience diarrhea.

Constipation

While some people experience diarrhea, others may have the opposite effect and experience constipation. This is also related to the changes in digestive speed and function caused by the medication.

Decreased Appetite

A reduction in appetite is an expected effect of how orforglipron works. By signaling fullness to the brain and slowing stomach emptying, the medication is designed to make you feel satisfied with less food. While this is part of its therapeutic effect for weight management, it is still important to ensure you are getting adequate nutrition.

Indigestion, Burping, and Bloating

Other common digestive complaints include indigestion (dyspepsia), increased burping, and a feeling of abdominal bloating or fullness. These are also tied to the slowed gastric emptying that is characteristic of GLP-1 medications.

Strategies for Managing Common Side Effects

If you and your doctor decide that orforglipron is right for you, there are common strategies that may help manage these initial side effects.

Gradual Dosing (Titration)

Orforglipron is started at 0.8 mg once daily and increased no faster than every 30 days, as your prescriber decides. This "start low, go slow" approach gives your body time to adapt, which can reduce the intensity of gastrointestinal side effects. Do not change your dose yourself.

Dietary Adjustments

Many people find that making small changes to their eating habits can help. This might include eating smaller, more frequent meals instead of three large ones, avoiding high-fat or greasy foods, and stopping eating as soon as you begin to feel full. Listening to your body’s new fullness cues is key.

Staying Hydrated

Drinking plenty of water throughout the day is important, especially if you are experiencing vomiting or diarrhea, to prevent dehydration.

Serious but Less Common Side Effects

While most side effects are mild and transient, all medications carry a risk of more serious adverse events. These were reported much less frequently in clinical trials but are important to be aware of.

Pancreatitis

Inflammation of the pancreas, known as pancreatitis, is a rare but serious risk associated with the GLP-1 class of drugs. Symptoms include severe, persistent pain in your abdomen that may radiate to your back, with or without vomiting. If you experience these symptoms, you should seek medical attention right away.

Gallbladder Problems

Some studies have shown that GLP-1 medications may increase the risk of gallbladder problems, such as gallstones or gallbladder inflammation (cholecystitis). Symptoms can include pain in the upper right side of your stomach, fever, and yellowing of the skin or eyes (jaundice).

Potential Risk of Thyroid C-Cell Tumors

Orforglipron's US label carries the same boxed warning as other GLP-1 receptor agonists. In rodent studies, GLP-1 medicines that are active in rodents caused thyroid C-cell tumours; orforglipron is not active in rats or mice and did not cause tumours in them, but the relevance to humans is unknown. Because of this potential risk, orforglipron should not be taken by people with a personal or family history of medullary thyroid carcinoma (MTC) or by those with a rare condition called Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). Report a lump in the neck, trouble swallowing, shortness of breath or a persistent hoarse voice.

Low Blood Sugar

If you also take insulin or a sulfonylurea, orforglipron can increase the risk of low blood sugar, including severe episodes. Your clinician may lower the dose of those medicines. Signs include shakiness, sweating, confusion and a fast heartbeat.

Diabetic Eye Disease

If you have type 2 diabetes and a history of diabetic retinopathy, your clinician should monitor your eyes. Report any change in your vision.

Surgery and Sedation

GLP-1 medicines slow stomach emptying, which raises the risk of inhaling stomach contents during general anaesthesia or deep sedation. Tell your care team that you take orforglipron before any planned procedure.

Pregnancy and Contraception

Orforglipron may harm an unborn baby, so effective contraception is advised during treatment; stop it and contact your clinician if you become pregnant. Because it can affect how oral contraceptive pills are absorbed, the US label advises switching to a non-oral method, or adding a barrier method such as condoms, for 30 days after starting and for 30 days after each dose increase.

Interactions With Other Medicines

Some medicines that strongly affect the liver enzyme CYP3A4 change orforglipron levels, and orforglipron can affect simvastatin and other oral medicines. Tell your prescriber and pharmacist about everything you take.

Kidney Problems

In people who experience severe vomiting and diarrhea, dehydration can sometimes lead to acute kidney injury. Maintaining good hydration is a crucial preventative measure.

Serious Allergic Reactions

As with any drug, there is a risk of a serious allergic reaction. Seek immediate medical help if you experience symptoms like swelling of your face, lips, tongue, or throat; problems breathing or swallowing; severe rash or itching; fainting or feeling dizzy; or a very rapid heartbeat.

When to Talk to Your Doctor

Open communication with your healthcare team is essential for managing your health safely. Get urgent medical help for severe stomach pain that does not go away, signs of a serious allergic reaction, or severe low blood sugar.

You should contact your provider if:

• Common side effects are severe or do not improve after a few weeks.
• You experience any symptoms of a serious side effect, such as pain in the upper right abdomen, fever or yellowing of the skin or eyes.
• Vomiting or diarrhoea stops you keeping fluids down, or you are passing much less urine.
• You are struggling to eat or drink enough due to side effects.
• You have any other questions or concerns about your treatment.

This guide is for informational purposes and is not a substitute for professional medical advice. Every individual's experience with a medication can be different. Consult your healthcare provider before starting any medication.

Sources

• The New England Journal of Medicine: Phase 2 Trial of Orforglipron in Adults with Obesity (https://www.nejm.org/doi/full/10.1056/NEJMoa2302392)
• The New England Journal of Medicine: Orforglipron, an Oral Small-Molecule GLP-1 Receptor Agonist for Obesity Treatment (ATTAIN-1), 2025 (https://doi.org/10.1056/NEJMoa2511774)
• FOUNDAYO (orforglipron) US prescribing information, Eli Lilly, revised July 2026 (https://pi.lilly.com/us/foundayo-uspi.pdf)
• ClinicalTrials.gov study search for orforglipron (https://clinicaltrials.gov/)
• ClinicalTrials.gov: ATTAIN-2, orforglipron in adults with obesity or overweight and type 2 diabetes (https://clinicaltrials.gov/study/NCT05872620)
• Eli Lilly pipeline overview for orforglipron: https://www.lilly.com/our-medicines/pipeline